Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) – Stock analysts at SVB Leerink upped their FY2024 earnings per share (EPS) estimates for shares of Reata Pharmaceuticals in a research report issued to clients and investors on Monday, June 12th. SVB Leerink analyst J. Schwartz now forecasts that the company will post earnings per share of […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) CAO Bhaskar Anand sold 2,343 shares of Reata Pharmaceuticals stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $102.11, for a total value of $239,243.73. Following the completion of the sale, the chief accounting officer now owns 24,898 shares in […]
Reata Pharmaceuticals, Inc. (NASDAQ:RETA – Get Rating) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating on the company. The […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its price target hoisted by Barclays from $90.00 to $98.00 in a research note published on Wednesday, The Fly reports. Several other analysts also recently commented on the stock. SVB Securities raised their price objective on shares of Reata Pharmaceuticals from $35.00 to $75.00 in a research report […]
Reata Pharmaceuticals (NASDAQ:RETA – Get Rating) had its target price raised by Stifel Nicolaus from $105.00 to $115.00 in a research report report published on Thursday, The Fly reports. A number of other research analysts have also commented on RETA. Citigroup lifted their price objective on shares of Reata Pharmaceuticals from $53.00 to $120.00 and […]